atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
The patients who watched the personalized AI avatar videos showed better understanding of their treatment plan, a greater ability to engage with health care decisions, and reduced stress compared to those who watched the standard educational video.
Read more here.
Once cancer has begun to spread within the body (metastasise) it generally becomes harder to treat and survival rates are lower. The new research focuses on patients with oligometastatic breast cancer, meaning a few small secondary tumors have broken away…
Attendees
Sponsors and Exhibitors
Contact us